SPRY2 loss enhances ErbB trafficking and PI3K/AKT signalling to drive human and mouse prostate carcinogenesis
Article first published online: 31 MAY 2012
Copyright © 2012 EMBO Molecular Medicine
EMBO Molecular Medicine
Volume 4, Issue 8, pages 776–790, August 2012
How to Cite
Gao, M., Patel, R., Ahmad, I., Fleming, J., Edwards, J., McCracken, S., Sahadevan, K., Seywright, M., Norman, J., Sansom, O. and Leung, H. Y. (2012), SPRY2 loss enhances ErbB trafficking and PI3K/AKT signalling to drive human and mouse prostate carcinogenesis. EMBO Mol Med, 4: 776–790. doi: 10.1002/emmm.201100944
- Issue published online: 3 AUG 2012
- Article first published online: 31 MAY 2012
- Manuscript Accepted: 20 APR 2012
- Manuscript Revised: 6 APR 2012
- Manuscript Received: 10 SEP 2011
- Funded Access
Detailed facts of importance to specialist readers are published as ”Supporting Information”. Such documents are peer-reviewed, but not copy-edited or typeset. They are made available as submitted by the authors.
Please note: Wiley-Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.